Ridaforolimus - Medinol

Drug Profile

Ridaforolimus - Medinol

Alternative Names: AP 23573; BioNIR; Deforolimus; EluNIR; EluNIR™ Ridaforolimus-Eluting Coronary Stent System; Jenzyl; MedJ-01; MK-8669; NirSupreme

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Medinol; Merck & Co
  • Class Antineoplastics; Macrolides; Vascular disorder therapies
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Coronary artery restenosis
  • Preregistration Submission Withdrawal Sarcoma
  • Discontinued Breast cancer; Cancer; Endometrial cancer; Neurodegenerative disorders; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 19 Apr 2018 Merck terminates phase II trial in Breast cancer (combination therapy, late-stage disease, metastatic disease, second-line therapy) (NCT01605396)
  • 16 Dec 2017 Medinol completes the BIONICS trial for Coronary artery restenosis in Israel (NCT02834806)
  • 26 Oct 2017 Phase-III clinical trials in Coronary artery restenosis in Israel, Belgium, Canada, Italy, Netherlands, Poland and Spain (Intra-arterial) before October 2017 (NCT02736344)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top